Skip to main content

Compensation package for clinical trial victims in the offing


NEW DELHI: India will soon quantify the amount of compensation to be paid by pharmaceutical companies, if a volunteer dies or gets injured during a clinical trial.

On October 10, the Drug Technical Advisory Board (DTAB) gave its nod to the Central Drugs Standard Control Organization (CDSCO) to prepare a "compensation chart" or extensive guidelines that will specify the amount to be paid.

Ethical committees of the company will have to decide the quantum of compensation on the basis of these guidelines.

The compensation has to be paid by the trial's sponsor or its representative within 90 days of the death or injury to the victim or the next of h/his kin. In the first 30 days, the firm will have to prove to the ethics panel that the death or injury wasn't due to the drug, else it has to pay.

In India, pharma companies pay compensation "according to their will" that varies between Rs 1 lakh and Rs 10 lakhs since "no set parameters have been laid down".

 

The CDSCO will prepare the compensation guidelines after consulting the Motor Vehicles Act, Railways and the Workers Compensation Act.

Union health ministry officials say it will take another three months to notify the guidelines. "When a 70-year-old terminally ill patient dies during a clinical trial, the compensation should be less than that given to a 22-year-old in the first stage of the same ailment. The youngster could be the family's sole bread-winner and would have lived longer had it not for the adverse drug reaction. The guidelines will quantify who should get how much compensation," a ministry official told TOI.

"Both these patients could get the same amount. However, the pharma company might have decided on an abysmally low package. Once the guidelines are in place, the division of compensation will be fair," he added.

Families of the 22 clinical trial victims last year were paid around Rs 50 lakh by 10 pharma companies.
Compensation ranged from Rs 1.08 lakh to Rs 10 lakh. Most of the families received Rs 1.5 lakh and Rs 2.5 lakh as a one-time package.

Initially, the companies had not paid compensation for majority of these deaths. Then, DCGI Dr Surinder Singh issued an ultimatum to the errant firms: pay up or all other trials would be suspended.

The companies who paid the compensation included well-known names like Wyeth, Quintiles, Lilly, Amgen, Bayer, Bristol Mayer, Sanofi, PPD and Pfizer. Pharma companies have all along been blamed for not paying compensation to hapless clinical trial victims.

The Indian Council of Medical Research recently framed draft guidelines for compensation to participants for research-related injury. Mothers, who because of clinical trials, lose or cause harm to their unborn child may be able to demand compensation from researchers conducting the trials.

Compensation has to be paid, irrespective of whether injury was foreseeable/predictable, and that the research participant had freely consented in writing about participating in it.

Compensation will have to be provided to the research participants when temporary or permanent injury occurs due to participation in the clinical study.

Compensation also has to be paid when the injury is caused by a procedure that has been undertaken to manage an adverse reaction occurring during the research.

Defining "compensation", the draft says it could be in form of payment for immediate medical/surgical management of research-related injuries, compensation for research-related injuries leading to temporary or permanent disabilities or compensation to legal heir/lawful guardian in case of death.

"The payment will be the responsibility of the investigator/institution," it says.

Besides, the Informed Consent Document (ICD) will have to state that the research participant has the right to claim compensation in case of research-related injuries and whom to contact for it.

Article source: Times of India

Comments

Popular posts from this blog

Isotretinoin in India: A tragedy in the offing

Isotretinoin in India: A tragedy in the offing
Wednesday, March 28, 2007 08:00 IST 
Seema Thakral

Isotretinoin is the drug of choice for severe calcitrant cystic acne vulgaris, which often causes scarring and depression from disfigurement. Isotretinoin has been called "the greatest medical advance of the 1980's." A majority of patients with acne are permanently cleared after a four to five months course of treatment. It has also been used off-label for a variety of oncology uses including: cervical cancer, head and neck cancer, squamous cell cancer of the skin, juvenile chronic myelogenous leukemia (CML), and neuroblastoma. However, the drug is a proved teratogen and carries a significant risk of birth defects, if it taken during pregnancy. Birth defects, which have been documented following isotretinoin exposure include abnormalities of the face, eyes, ears, skull, central nervous system, cardiovascular system, and thymus and parathyroid glands. There is an increased risk …

FDA Restricts Use of Diabetes Drug Avandia

FDA Decides Not to Ban Avandia, but Puts Restrictions on How It’s Used.
By Daniel J. DeNoon
WebMD Health News

Sept. 23, 2010 -- The FDA will not ban Avandia -- but stringent restrictions will make it far harder for doctors to prescribe the safety-troubled diabetes drug.

The European Medicines Agency took harsher action. European sales of Avandia-containing drugs will be suspended over the next few months, although the agency did not formally withdraw approval.

The 600,000 U.S. patients currently taking Avandia can continue to take the drug only if their doctors officially attest that their patients understand the risks, that the drug is helping them, and that no other diabetes drug can keep their blood sugar under control.

New Avandia prescriptions can only be written for patients who, for medical reasons, cannot take Actos. Actos, a diabetes medication in the same class as Avandia, does not cause the heart problems linked to Avandia.

"Avandia will be available to new pat…

The Connection Between Sedatives and Fractures in Elderly Patients

Johns Hopkins Health Alerts:
Prescription Drugs
The Connection Between Sedatives and
Fractures in Elderly Patients
All drugs have potential side effects. Indeed, at some point you've probably squinted down the laundry list of possible side effects on the package insert of your medications. Common drug-related side effects include blurred vision, drowsiness, dizziness, dry mouth, heart palpitations, erectile dysfunction, memory impairment, and nervousness. Fortunately, many of these drug side effects occur in only small numbers of people. Now researchers have called into question the connection between sedatives which can cause dizziness and the potential for falls in elderly patients. They point out that well-meant policies discouraging sedative use in older people to prevent falls and fractures may not be necessary. Starting in 1989, New York State required doctors to fill out prescriptions in triplicate for benzodiazepines, the most widely used class of sedatives. Tw…